Products for Research Use Only

Niclosamide-d3

CAT: 0804-HY-B0497S2Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0497S2Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Niclosamide-d3 (BAY2353-d3) is deuterium labeled Niclosamide. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].
CAS Number
2665663-60-3
Product Name Alternative
BAY2353-d3
UNSPSC
12352005
Target
Antibiotic; Isotope-Labeled Compounds; Parasite; STAT
Related Pathways
Anti-infection; JAK/STAT Signaling; Others; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Infection; Cancer
Smiles
O=C(NC1=C([2H])C([2H])=C([N+]([O-])=O)C([2H])=C1Cl)C2=CC(Cl)=CC=C2O
Molecular Formula
C13H5D3Cl2N2O4
Molecular Weight
330.14
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[3]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[4]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[5]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[6]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products

Popular Products